Table 4 Outcomes of treatment groups
Treatment Outcomes | Definitive ExRT (n = 72) | RP (n = 48) | p |
|---|---|---|---|
BF n (%) | 16 (21.4) | 25 (52.1) | < 0.001 |
Mean BFFS (months) | 97.8 ± 5.9 | 34.4 ± 3.9 | < 0.001 |
3 year BFFS (%) (95% CI) | 89.3 (95 81.7–96.9) | 50.6 (36.1–65.1) |  |
5 year BFFS (%) (95% CI) | 78.1 (66.7–89.5) | 38.5 (20.1–56.9) |  |
DM n (%) | 11 (15.3) | 4 (8.3) | 0.399 |
Mean DMFS (months) | 106.6 ± 5.1 | 118.5 ± 4.9 | 0.992 |
3-year DMFS (%) (95% CI) | 93.8 (87.9–99.7) | 90.9 (82.4–99.4) |  |
5-year DMFS (%) (95% CI) | 89.5 (81.4–97.6) | 90.9 (82.4–99.4) |  |
Cancer-specific mortality n (%) | 5 (6.9) | 2 (4.2) | 0.701 |
Mean CSS (months) | 116.9 ± 5.1 | 109.9 ± 14.0 | 0.693 |
3 year CSS (%) | 96.8 (92.5–100.0) | 96.9 (90.8–100.0) |  |
5 year CSS (%) | 94.1 (87.2–100.0) | 96.9 (90.8–100.0) |  |
All-cause mortality n (%) | 9 (12.5) | 7 (14.6) | 0.788 |
Mean OS (months) | 110.9 ± 4.6 | 92.3 ± 13.4 | 0.160 |
3 year OS (%) (95% CI) | 94.1 (88.4–99.7) | 87.2 (76.6–97.9) |  |
5 year OS (%) (95% CI) | 86.8 (77.2–96.3) | 87.2 (76.6–97.9) |  |